Developer docs
API playgroundTry for free, no card

Search company profiles

Zosano Pharma

Full company profile

uuid0005ey4

Namestring
Zosano Pharma
Legal namestring
Zosano Pharma Corporation
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Fremont, California, that has developed a proprietary microneedle-based transdermal drug delivery platform. The company's core technology enables painless, minimally invasive administration of therapeutics through the skin, with a value proposition centered on improved patient compliance and reduced cold chain requirements. In April 2021, Zosano extended this platform by launching a temperature-stable vaccine delivery patch designed to eliminate cold chain storage requirements for vaccine distribution. The company's identified primary therapeutic focus is acute migraine treatment, positioning it in the horizontal use-case segment of migraine patients.

As a publicly traded company on NASDAQ under ticker ZSAN, Zosano has historically funded operations through equity financings rather than product revenue. Across at least 14 disclosed funding rounds between 2007 and 2022, the company raised cumulative proceeds exceeding $250 million, with the most recent being a $15.4 million public offering of common stock and warrants in February 2022 priced at $0.30 per unit. Proceeds from the February 2022 raise were explicitly designated for pre-commercialization activities and general corporate purposes, confirming the company had not yet generated product revenue at the time of its last capital raise. The company operates in the microneedle drug delivery market alongside larger competitors including 3M and Becton Dickinson.

A material concern is signaled by the fact that the company's website domain (zosanopharma.com) has expired and is currently parked with GoDaddy as of the data capture, indicating probable operational cessation or material disruption following the February 2022 financing. Leadership disclosure is limited to two named executives: Chris Kruegar (Chief Business Officer) and Peter Daddona (Executive Vice President and Chief Scientific Officer). Given the expired domain and absence of post-2022 operational signals, the company's current operating status is uncertain.

Short descriptiontext

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company that develops proprietary microneedle-based transdermal drug delivery systems, primarily targeting acute migraine patients. As of its February 2022 capital raise, the company remained pre-commercialization, with website activity subsequently ceased.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
microneedle drug delivery, transdermal drug delivery, biopharmaceutical products, vaccine delivery patches, pharmaceutical drug delivery
Industry3 codes
PRIMARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Transdermal drug delivery systems
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zosano Pharma develops a proprietary microneedle transdermal drug delivery technology platform for pharmaceutical and vaccine administration. The company is pre-commercialization, working on a temperature-stable vaccine delivery patch and broader drug delivery applications targeting pain management and acute migraine relief.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Zosano Pharma is a pharmaceutical company specializing in microneedle-based drug delivery systems. The company's primary product offering is a temperature-stable vaccine delivery patch introduced in April 2021. The company operates in the broader microneedle drug delivery systems market, competing with established players like 3M Company, Becton Dickinson and Company, and Nanopass Technologies. Zosano Pharma's microneedle technology enables painless drug administration through the skin.

Product and service2 records
1Temperature-Stable Vaccine Delivery Patch
CategoryVaccine delivery
Description

A microneedle-based patch for vaccine administration that is temperature-stable, designed to eliminate the need for cold chain storage and provide painless, self-applicable delivery for healthcare providers and patients.

2Microneedle Transdermal Drug Delivery Platform
CategoryDrug delivery technology
Description

A proprietary transdermal microneedle delivery platform for pharmaceutical compounds, intended to enable needle-free, painless drug administration with potential applications in pain management and acute migraine relief.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the named direct competitors of Zosano in the microneedle drug delivery market. BD has a much larger medical device and drug delivery franchise, making it the most relevant scaled direct peer for Zosano's microneedle platform.

TypeDirect peer
Description

Named as a direct competitor in the global microneedle drug delivery market. 3M's drug delivery and life sciences businesses are directly comparable to Zosano's microneedle-based delivery approach.

TypeDirect peer
Description

Direct competitor explicitly cited in Zosano's product overview. Nanopass develops microneedle-based delivery systems for vaccines and therapeutics and is the closest pure-play microneedle peer.

TypeEmerging player
Description

Develops high-density microarray patches for vaccine and therapeutic delivery — closely aligned with Zosano's temperature-stable vaccine patch concept and the broader needle-free delivery thesis.

TypeEmerging player
Description

Specializes in transdermal drug delivery, including microneedle-based products. Operates in the same transdermal/microneedle delivery category as Zosano, though with a broader portfolio and more advanced commercialization.

TypeBroad incumbent
Description

A long-established transdermal drug delivery company (now part of Hisamitsu) specializing in patch-based pharmaceutical delivery. A comparable, larger incumbent in the broader transdermal delivery space Zosano targets.

TypeBroad incumbent
Description

One of the world's largest transdermal patch and oral thin-film manufacturers. Comparable as a scaled, established player in transdermal drug delivery technology that Zosano is also addressing.

TypeBroad incumbent
Description

Specialty pharmaceutical company focused on pain management and neurology, an area that overlaps with Zosano's acute migraine use case. Comparable as a specialty pharma commercializing differentiated pain/neurology therapies.

TypeEmerging player
Description

Specialty pharmaceutical company developing CNS and pain therapies, including migraine-related programs. Comparable to Zosano's migraine / neurology focus area within specialty pharma.

TypeEmerging player
Description

Specialty biopharmaceutical company developing therapeutics in endocrinology and HIV, with a smaller-scale, pre-commercial-to-commercial profile comparable to Zosano's specialty pharma stage.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zosano Pharma

Transdermal drug delivery systemszosanopharma.com

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company that develops proprietary microneedle-based transdermal drug delivery systems, primarily targeting acute migraine patients. As of its February 2022 capital raise, the company remained pre-commercialization, with website activity subsequently ceased.

What Zosano Pharma does

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Fremont, California, that has developed a proprietary microneedle-based transdermal drug delivery platform. The company's core technology enables painless, minimally invasive administration of therapeutics through the skin, with a value proposition centered on improved patient compliance and reduced cold chain requirements. In April 2021, Zosano extended this platform by launching a temperature-stable vaccine delivery patch designed to eliminate cold chain storage requirements for vaccine distribution. The company's identified primary therapeutic focus is acute migraine treatment, positioning it in the horizontal use-case segment of migraine patients.

As a publicly traded company on NASDAQ under ticker ZSAN, Zosano has historically funded operations through equity financings rather than product revenue. Across at least 14 disclosed funding rounds between 2007 and 2022, the company raised cumulative proceeds exceeding $250 million, with the most recent being a $15.4 million public offering of common stock and warrants in February 2022 priced at $0.30 per unit. Proceeds from the February 2022 raise were explicitly designated for pre-commercialization activities and general corporate purposes, confirming the company had not yet generated product revenue at the time of its last capital raise. The company operates in the microneedle drug delivery market alongside larger competitors including 3M and Becton Dickinson.

A material concern is signaled by the fact that the company's website domain (zosanopharma.com) has expired and is currently parked with GoDaddy as of the data capture, indicating probable operational cessation or material disruption following the February 2022 financing. Leadership disclosure is limited to two named executives: Chris Kruegar (Chief Business Officer) and Peter Daddona (Executive Vice President and Chief Scientific Officer). Given the expired domain and absence of post-2022 operational signals, the company's current operating status is uncertain.

Zosano Pharma firmographics

Firmographics
Name
Zosano Pharma
Legal name
Zosano Pharma Corporation
Website
https://zosanopharma.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company that develops proprietary microneedle-based transdermal drug delivery systems, primarily targeting acute migraine patients. As of its February 2022 capital raise, the company remained pre-commercialization, with website activity subsequently ceased.
Ownership category
akta.pro rank

Zosano Pharma industry classification

Industry
Product category
Transdermal drug delivery systems
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Microneedle drug delivery
  • Transdermal drug delivery
  • Biopharmaceutical products
  • Vaccine delivery patches
  • Pharmaceutical drug delivery

Where Zosano Pharma is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Markets served

Zosano Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Zosano Pharma product offering

Product offering

Core offering

Zosano Pharma develops a proprietary microneedle transdermal drug delivery technology platform for pharmaceutical and vaccine administration. The company is pre-commercialization, working on a temperature-stable vaccine delivery patch and broader drug delivery applications targeting pain management and acute migraine relief.

Product overview

Zosano Pharma is a pharmaceutical company specializing in microneedle-based drug delivery systems. The company's primary product offering is a temperature-stable vaccine delivery patch introduced in April 2021. The company operates in the broader microneedle drug delivery systems market, competing with established players like 3M Company, Becton Dickinson and Company, and Nanopass Technologies. Zosano Pharma's microneedle technology enables painless drug administration through the skin.

Differentiator

Problem solved

Functional benefit

Products and services

  • Temperature-Stable Vaccine Delivery Patch A microneedle-based patch for vaccine administration that is temperature-stable, designed to eliminate the need for cold chain storage and provide painless, self-applicable delivery for healthcare providers and patients.
  • Microneedle Transdermal Drug Delivery Platform A proprietary transdermal microneedle delivery platform for pharmaceutical compounds, intended to enable needle-free, painless drug administration with potential applications in pain management and acute migraine relief.

Companies that use Zosano Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Zosano Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Zosano Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Zosano Pharma competitors and assessment

Company assessment

Direct peers

  • Becton, Dickinson and Company (BD): One of the named direct competitors of Zosano in the microneedle drug delivery market. BD has a much larger medical device and drug delivery franchise, making it the most relevant scaled direct peer for Zosano's microneedle platform.
  • 3M Company: Named as a direct competitor in the global microneedle drug delivery market. 3M's drug delivery and life sciences businesses are directly comparable to Zosano's microneedle-based delivery approach.
  • Nanopass Technologies: Direct competitor explicitly cited in Zosano's product overview. Nanopass develops microneedle-based delivery systems for vaccines and therapeutics and is the closest pure-play microneedle peer.

Emerging players

  • Vaxxas: Develops high-density microarray patches for vaccine and therapeutic delivery — closely aligned with Zosano's temperature-stable vaccine patch concept and the broader needle-free delivery thesis.
  • Corium (adhesive-based transdermal and microneedle delivery): Specializes in transdermal drug delivery, including microneedle-based products. Operates in the same transdermal/microneedle delivery category as Zosano, though with a broader portfolio and more advanced commercialization.
  • Tonix Pharmaceuticals: Specialty pharmaceutical company developing CNS and pain therapies, including migraine-related programs. Comparable to Zosano's migraine / neurology focus area within specialty pharma.
  • Theratechnologies: Specialty biopharmaceutical company developing therapeutics in endocrinology and HIV, with a smaller-scale, pre-commercial-to-commercial profile comparable to Zosano's specialty pharma stage.

Broad incumbents

  • Noven Pharmaceuticals: A long-established transdermal drug delivery company (now part of Hisamitsu) specializing in patch-based pharmaceutical delivery. A comparable, larger incumbent in the broader transdermal delivery space Zosano targets.
  • LTS Lohmann Therapie-Systeme: One of the world's largest transdermal patch and oral thin-film manufacturers. Comparable as a scaled, established player in transdermal drug delivery technology that Zosano is also addressing.
  • BioDelivery Sciences International (BDSI, now part of Collegium Pharmaceutical): Specialty pharmaceutical company focused on pain management and neurology, an area that overlaps with Zosano's acute migraine use case. Comparable as a specialty pharma commercializing differentiated pain/neurology therapies.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Zosano Pharma social profiles

Digital presence

Zosano Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zosano Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Zosano Pharma funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zosano Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zosano Pharma

What does Zosano Pharma do?

Zosano Pharma develops a proprietary microneedle transdermal drug delivery technology platform for pharmaceutical and vaccine administration. The company is pre-commercialization, working on a temperature-stable vaccine delivery patch and broader drug delivery applications targeting pain management and acute migraine relief.

Is Zosano Pharma a public or private company?

Zosano Pharma is a public company. It is classified as public and is currently operating.

When was Zosano Pharma founded?

Zosano Pharma was founded in 2006. It employs 11 to 50 people.

Where is Zosano Pharma based?

Zosano Pharma is headquartered in Fremont, United States, in the North America region.

Who are Zosano Pharma's main competitors?

Direct peers on record are Becton, Dickinson and Company (BD), 3M Company and Nanopass Technologies. Emerging players are Vaxxas, Corium (adhesive-based transdermal and microneedle delivery), Tonix Pharmaceuticals and Theratechnologies. Broad incumbents are Noven Pharmaceuticals, LTS Lohmann Therapie-Systeme and BioDelivery Sciences International (BDSI, now part of Collegium Pharmaceutical).

Does Zosano Pharma have an API?

No public API is recorded for Zosano Pharma.

What industry is Zosano Pharma in?

Zosano Pharma's product category is Transdermal drug delivery systems. Its primary akta.pro industry code is HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral), with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMicroneedle Drug Delivery Systems Market Players - Competitive Positioning, Strategic Strengths & Investor OutlookThe global microneedle drug delivery systems market is rapidly growing, with projections reaching USD 10.85 billion by 2032, driven by technological advancements, strategic collaborations, and increasing demand for minimally invasive drug delivery methods. Major companies like 3M, Becton, Dickinson, Zosano Pharma, and Nanopass Technologies are actively investing in product innovation, geographic expansion, and strategic partnerships.EIN PresswireMicroneedle Drug Delivery Systems Market size to Surpass USD 10.85 Billion by 2032, Maximize Market Research AnalysisMaximize Market Research published a report projecting the global microneedle drug delivery systems market to grow from USD 6.22 billion in 2024 to USD 10.85 billion by 2032, representing a CAGR of 7.2%, driven by rising demand for pain-free, minimally invasive drug delivery technologies. Key developments include 3M Company's September 2023 launch of a sustained-release microneedle patch, Becton, Dickinson and Company's August 2023 strategic collaboration for sensor-enabled microneedle platforms, and Zosano Pharma Corporation's April 2021 introduction of a temperature-stable vaccine delivery patch. The report identifies North America as the dominant regional market, followed by Europe, with high development costs and complex FDA/EMA regulatory approvals cited as primary growth challenges.GlobeNewswireDelisting of Securities of Alberton Acquisition Corporation; Zosano Pharma Corporation; Electric Last Mile Solutions, Inc.; 4D pharma plc; and Enjoy Technology, Inc. from The Nasdaq Stock MarketNasdaq announced delistings for Alberton Acquisition Corporation, Zosano Pharma Corporation, Electric Last Mile Solutions, Inc., 4D pharma plc, and Enjoy Technology, Inc. The securities had been suspended and not traded since April 26, June 13, June 23, July 7, and July 11, 2022, respectively. Nasdaq will file a Form 25 with the SEC, and the delistings take effect ten days after filing.BenzingaWhy Zosano Pharma Shares Are Getting Hammered TodayZosano Pharma Corp filed a voluntary Chapter 11 bankruptcy petition, causing its shares to drop 44.35% to $0.98. The clinical-stage biopharmaceutical company will continue operating as a debtor-in-possession and intends to sell substantially all of its assets during the bankruptcy proceedings.GlobeNewswireMicroneedle Drug Delivery Systems Global Market Report 2022The global microneedle drug delivery systems market is projected to grow from $3.26 billion in 2021 to $3.60 billion in 2022, with a CAGR of 10.3%, and to $6.64 billion by 2026 at a CAGR of 16.6%. Growth is driven by increasing vaccine demand and research, with major players including 3M and Zosano Pharma.trib.alZosano Pharma cuts staff 31%, the latest layoffs in a wave of biotech belt-tighteningZosano Pharma cut about 31% of its staff, leaving 31 employees, after the FDA rejected its migraine drug M207 application. The company has $11 million in cash and is exploring strategic alternatives, including a sale or joint venture.BenzingaZosano Lays Off ~30% Of Its Workforce After FDA Rejection Of Migraine Drug ApplicationZosano Pharma Corp reduced 31% of its workforce following FDA rejection of its migraine drug resubmission for Qtrypta (M207), a novel delivery formulation of zolmitriptan. The company now employs 21 R&D staff down from 29, and held $11 million in cash as of December 2021, raising questions about its ability to fund operations. The FDA's rejection cited incomplete response to deficiencies outlined in the agency's 2020 rejection, and company filings indicate additional hurdles remain even if the drug eventually wins approval.FierceBiotechZosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmissionZosano Pharma laid off 31% of its staff after the FDA rejected its resubmission of migraine drug M207. The company's shares fell nearly 7% to under 20 cents, and it raised $15.4 million in a public offering. Zosano is still in discussions with the FDA about pursuing approval.BenzingaFDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares PlungeThe FDA has issued a second rejection letter to Zosano Pharma regarding its M207 zolmitriptan microneedle system drug application, finding the resubmission incomplete because the pharmacokinetic bridge strategy relying primarily on a Phase 1 PK study was not acceptable. The agency identified specific design differences between the company's Study CP-2021-001 and the re-dosing criteria outlined in the labeling instructions for the reference drug Zomig Nasal Spray 5 mg. Facing potential resource constraints, the company has retained SierraConstellation Partners to explore financial and strategic alternatives while shares dropped 31.9% to $0.15.